Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study

Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study

ABSTRACT COVID-19 convalescent plasma (CCP) was an early and widely adopted putative therapy for severe COVID-19. Results from randomized control trials and observational studies have failed to demonstrate a clear therapeutic role for CCP for severe acute respiratory syndrome coronavirus 2 (SARS-CoV...

Full description

Bibliographic Details
Main Authors: Luther A. Bartelt, Alena J. Markmann, Bridget Nelson, Jessica Keys, Heather Root, Heather I. Henderson, JoAnn Kuruc, Caroline Baker, D. Ryan Bhowmik, Yixuan J. Hou, Lakshmanane Premkumar, Caleb Cornaby, John L. Schmitz, Susan Weiss, Yara Park, Ralph Baric, Aravinda M. de Silva, Anne Lachiewicz, Sonia Napravnik, David van Duin, David M. Margolis
Format: Article
Language:English
Published: American Society for Microbiology 2022-10-01
Series:mBio
Subjects:
antibodies
SARS-CoV-2
convalescent plasma
immunology
neutralizing antibodies
Online Access:https://journals.asm.org/doi/10.1128/mbio.01751-22

Internet

https://journals.asm.org/doi/10.1128/mbio.01751-22

Similar Items